Canakinumab: Anti-inflammatory Drug Could Reduce Risk Of Heart attack,And Cancer Study Find

Canakinumab is an anti-inflammatory drug (NSAIDs) works by targeting an interleukin involved in the inflammatory pathway, that has been related to the augmented risk of cardiovascular events in previous research.
- This drug is already approved by Food and Drug Administration





